Sulfasalazine
- Generic Name
- Sulfasalazine
- Brand Names
- Azulfidine, Salazopyrin, Salazopyrin En-tabs
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14N4O5S
- CAS Number
- 599-79-1
- Unique Ingredient Identifier
- 3XC8GUZ6CB
- Background
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA). Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry ...
- Indication
In the US, sulfasalazine is indicated to treat mild to moderate ulcerative colitis and to prolong the remission period between acute attacks of ulcerative colitis. Sulfasalazine is also indicated as an adjunct therapy in severe ulcerative colitis.For the delayed-release tablet formulation, sulfasalazine is also indicated to treat rheumatoid arthritis in pedi...
- Associated Conditions
- Crohn's Disease (CD), Distal Ulcerative Colitis, Mild to Moderate Ulcerative Colitis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Proctitis, Rheumatoid Arthritis, Severe Ulcerative Colitis, Ulcerative Colitis in Remission
- Associated Therapies
- -
Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 2500
- Registration Number
- NCT03440892
- Locations
- 🇸🇪
Dept of Rheumatology and Inflammation research, Gothenburg, Sweden
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Flinders University
- Target Recruit Count
- 124
- Registration Number
- NCT03254589
- Locations
- 🇦🇺
Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia
Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 9
- Registration Number
- NCT03012763
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2021-07-27
- Target Recruit Count
- 136
- Registration Number
- NCT02930343
- Locations
- 🇮🇳
Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India
Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Zhixiang Huang
- Target Recruit Count
- 100
- Registration Number
- NCT02638896
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
- Conditions
- Interventions
- Other: Lab WorkDrug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)Drug: Certolizumab pegol (CDP870, tradename Cimzia)Drug: HydroxychloroquineDrug: SulfasalazineDrug: MedrolDrug: PrednisoneDrug: TriamcinoloneDrug: NaproxenDrug: LeflunomideDrug: MethotrexateDrug: humira
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 32
- Registration Number
- NCT02451748
- Locations
- 🇺🇸
Outpatient Care Center, Chicago, Illinois, United States
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02434861
- Locations
- 🇺🇸
Parexel Early Phase Unit, Baltimor, Maryland, United States
Very Early Versus Delayed Etanercept in Patients With RA
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 120
- Registration Number
- NCT02433184
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
Treatments Against RA and Effect on FDG-PET/CT
- Conditions
- Interventions
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 159
- Registration Number
- NCT02374021
- Locations
- 🇺🇸
IRIS Research and Development, Plantation, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.